GlycoMimetics - GLYC Income before deduction of interest, taxes and amortization

Graphic logo of glycomimetics.com (GLYC)

GlycoMimetics, Inc. (GLYC) possesses significant potential driven by its leukemia patents, as evidenced by the company's EBITDA. The value of reflects this status. However, risks remain tied to the dependence on the small-molecule R&D platform and a lack of revenue, meaning that expanding the drug portfolio only increases current laboratory expenses.

GlycoMimetics Inc. - GLYC Operating profit EBITDA (period 07/04/2022 - 11/10/2026)

GlycoMimetics (GLYC) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price GlycoMimetics Inc.|GLYC - Consensus Target
- issuer market value details:
Market Value GlycoMimetics|GLYC - Real Price to Acquire Entire Company
- book capitalization information:
Book Price of a Share GlycoMimetics|GLYC - Book Capitalization|Market Capitalization to Book Value Ratio glycomimetics.com|GLYC - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio GlycoMimetics, Inc.|GLYC - Long-Term Debt to Capital|Short-Term Indebtedness to Equity GlycoMimetics Inc.|GLYC - Company Aggregate Debts|Debts to Book Value GlycoMimetics|GLYC - Company Long-Term Liabilities|Amount of Current Liabilities GlycoMimetics|Immediate Liquidity glycomimetics.com
- financial results and valuation multiples details:
GLYC - Net Profit|Net Profit Forecast GlycoMimetics, Inc.|GLYC - Price to Earnings Ratio|Future Price to Earnings Multiple GlycoMimetics Inc.|GLYC - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio GlycoMimetics|GLYC - Operating profit EBITDA|Earnings per share for the trailing year GlycoMimetics|GLYC - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com|GLYC - Earnings per share growth in current year|Expected earnings per share trend next year GlycoMimetics, Inc.
Summary company analytics:GlycoMimetics, Inc.
Brand item of GlycoMimetics Inc.

Institutional capital assesses the investment attractiveness of GlycoMimetics, Inc. (GLYC) through the lens of the business's ability to generate real cash flow before taxes and depreciation. Monitoring EBITDA_Co allows for the exclusion of accounting adjustments, which is critical for a biotech firm facing drug trial failures and the need for emergency liquidity management to ensure the asset's survival.

Competitor analysis for GlycoMimetics, Inc.

Genmab Corp (GMAB) - Profit before interest, taxes and amortization|EXEL: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NUVL (nuvalent.com)|KYMR (Kymera) - Operating profit before deduction of amortization|IDYA: Company profit before taxes, interest and amortization|ELVN (Enliven Pharma) - Operating profit EBITDA|Operating profit EBITDA ORIC Corp|Profit before payment of interest, taxes and amortization Relay Therapeutics (RLAY)|NRIX (nurixtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TYRA (Tyra Biosciences)|Operating profit before depreciation charges Verastem Oncology|Monte Rosa Tx - Operating profit EBITDA|Profit before interest, taxes and amortization Cullinan Corp|IMRX (Immuneering Corporation) - Operating profit before deduction of amortization|CCCC: Company profit before taxes, interest and amortization|BDTX (Black Diamond Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Repare Therapeutics, Inc. RPTX|Operating profit EBITDA PMVP|karyopharm.com - Operating profit before amortization|Propanc Biopharma - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BGMS|AADI: Operating profit before deduction of amortization|Aileron Therapeutics - Company profit before taxes, interest and amortization|BPMC: Operating profit EBITDA|SpringWorks Therapeutics, Inc - Income before deduction of interest, taxes and amortization